Karma Biotechnologies is a Los Angeles startup
dedicated to solving autoimmunity, allergies, and food sensitivities
with our XAVINE™ tolerogenic vaccine platform.

  • General immune suppression is still the standard of care for most autoimmune disease patients and there is a critical unmet need to develop antigen-specific therapies that inhibit only the disease-causing rogue immune cells.
  • To meet this need, Karma is leveraging expertise in immunology and lipid nanoparticle engineering to develop tolerogenic vaccines designed to elicit antigen-specific immune tolerance in vivo.

SNIPR: KARMA’S PROPRIETARY LIPID NANOPARTICLE PLATFORM

SNIPR stands for Sub-Nanoparticle Intracellular Payload Release

SAFE

Low toxicity in vitro and in vivo

FLEXIBLE

Can deliver multiple payloads at once

STABLE

Unique process keeps SNIPR stable for weeks at 4oC

SCALABLE

Proprietary robotic manufacturing process

SNIPR PAYLOADS 

Their unique 3D structure allows loading of different payloads in controlled ratios

XAVINESTM : KARMA’S VACCINES FOR AUTOIMMUNITY

We designed our proprietary vaccine platform to restore tolerance in vivo

OVERVIEW: HOW XAVINESTM ARE DESIGNED TO WORK

Injected like a traditional vaccine to engineer system-wide antigen-specific tolerance

1

XavineTM nanoparticles injected

2

Antigen-presenting cells (APCs) engulf XavinesTM

3

XavinesTM train APCs to TOLERATE specific self-antigen(s)

4

Induced Treg cells mediate specific immune tolerance

5

Trained APCs migrate to lymph nodes/spleen

OUR TEAM

Karma is primed for success with a great mix of geeks and company builders

Andrew Gray, PhD

  • PhD in Immune tolerance induced by cancer
  • IndieBio alum
  • Directs Karma’s synthetic bio strategy

Alan Johnson, MBA, BS

  • Synthetic chemist with 20+ years experience
  • Iterates and validates Karma’s novel LNPs

Don Johnson, PhD

  • PhD in Biomedical Materials Science
  • NIH and IndieBio alum
  • Guides Karma’s LNP design strategy

Amber Kaplan, PhD

  • Ex-CSO of NKMax – guided 4 drugs to IND approval

Xazmin Custer, PhD

  • Metabolism & cell signaling expert

Mariana Uchoa, PhD

  • XavineTM research & development lead

ADVISORY BOARD

Karma has exceptional VC backers and is actively building an expert SAB

Todd Peterson, PhD

Former CSO of Allen Institute & former CTO of Viridos

James Treanor, PhD

Founding CEO, ADRx & 18 years at AMGEN

W. Martin Kast, PhD

Immune regulation guru

Paul Feldstein, PhD

Cell-specific expression expert

Andy Alexander, PhD DVM, DABT, MBA

FDA whisperer

Mike Siani-Rose

Project management and biopharma manufacturing pro

INVESTORS

CONTACT US

Karma Biotechnologies

LOCATION

370 Amapola Avenue, Suite 101
Torrance, CA 90501

EMAIL

andrew@karmabiotech.com